Glucose - instructions for use, dose, side effects, contraindications

Active substance:
Dextrose monohydrate (in terms of anhydrous substance)	100 g
Excipients:
Sodium chloride	0.26 g
A 0.1 M solution of hydrochloric acid	to pH 3.0-4.1
Water for injections	up to 1.0 liter
Theoretical osmolality	555 mOsm / l

Description:A clear, colorless liquid.

Pharmacotherapeutic group:Nutrition carbohydrate remedy

ATX: & nbsp

B.05.C Irrigation solutions

V.06.D Other medications for nutrition

V.04.C Other diagnostic preparations

Pharmacodynamics:

Participates in various metabolic processes in the body. The infusion of dextrose solutions partially replenishes the water deficiency. Dextrose, entering the tissue, phosphorylated, turning into glucose-6-phosphate, which is actively included in many parts of the body's metabolism.

Theoretical osmolarity: 10% dextrose - 555 mOsm / l.

Pharmacokinetics:

Dextrose, disintegrating into pyruvic or lactic acid (anaerobic glycolysis), is metabolized to carbon dioxide and water with the release of energy.

It is absorbed completely by the body, the kidneys are not excreted (the appearance in the urine is a pathological sign).

Additional pharmacokinetic properties are determined by the added preparations.

Indications:

- As a source of carbohydrates;

- with isotonic extracellular dehydration;

- for dilution and dissolution of parenterally administered drugs (as a base solution);

- for the prevention and treatment of moderate hypoglycemia.

Contraindications:

Hyperosmolar coma, hemodilution, extracellular hyperhydration or hypervolemia, hyperglycemia and hyperlactacidemia, severe renal failure (with oliguria or anuria), decompensated chronic heart failure, generalized edema and ascitic liver cirrhosis.

Carefully:

Decompensated chronic heart failure, hyponatremia, diabetes mellitus.

Pregnancy and lactation:

Dextrose 10% solution can be used during pregnancy and lactation provided that the electrolyte balance and fluid balance are monitored and are within physiological limits.

When adding other medicines, the possibility of using during pregnancy and during lactation is determined by the properties of the drug being added.

Dosing and Administration:

Intravenously (drip). The concentration and dose of the administered solution depend on the age, body weight and clinical state of the patient.The blood glucose content should be carefully monitored.

Recommended dose for adults and the elderly (body weight about 70 kg):

- as sources of carbohydrates, for the prevention and treatment of moderate hypoglycemia, with isotonic extracellular dehydration - from 500 to 3000 ml per day (7 to 40 ml / kg / day). To avoid exceeding the glucose disposal threshold in the body, the maximum dose should not exceed 5 mg / kg / min (3 ml / kg / h). The duration of treatment depends on the clinical condition of the patient.

- for dilution and dissolution of parenterally administered drugs (as a base solution) from 50 to 250 ml per dose of the drug administered. The dose, the rate of administration of the solution, and the duration of treatment depend on the solute.

Recommended doses for children and adolescents:

as sources of carbohydrates, for the prevention and treatment of moderate hypoglycemia, with isotonic extracellular dehydration:

- with a body weight of up to 10 kg - 100 ml / kg per day;

- with a body weight of 10 to 20 kg - 1000 ml + 50 ml per kg over 10 kg per day;

- with a body weight above 20 kg - 1500 ml + 20 ml for each kg over 20 kg per day.

To avoid exceeding the glucose utilization threshold in the body maximum daily dose should be:

- for premature and full-term newborns - from 6 to 11 ml / kg / h;

- for children from 1 to 3 years - from 5 to 8 ml / kg / h;

- for children from 4 to 6 years - from 5 to 7 ml / kg / h;

- for children from 7 to 10 years - from 4 to 7 ml / kg / h;

- for children over 11 years old - 4 ml / kg / h.

Duration of treatment it depends on the clinical condition of the patient.

For more complete assimilation of dextrose, administered in large doses, concurrently with it, insulin is administered with a short action, at the rate of 1 unit of short-acting insulin for 4-5 g of dextrose.

Depending on the clinical state of the patient, the rate of administration may be reduced to reduce the risk of osmotic diuresis.

Do not reconnect partially used containers (regardless of the amount of solution left in it).

Dispose of the containers after a single use.

Dispose of each unused dose.

Side effects:

Intravenous administration of a dextrose solution may lead to the development of an imbalance of fluid and electrolytes, including hypokalemia, hypermagnesemia, hypophosphatemia. Hyperglycemia and dehydration can be the result of an incorrect parenteral administration.Also, the occurrence of polyuria is likely.

With the technique of application, side effects such as fever, infection and soreness at the site of injection, thrombophlebitis or phlebitis, spreading from the site of injection, bruising and hypervolemia, can be associated.

When using dextrose solutions as a base solution (solvent) for other drugs, the probability of side effects is determined by the properties of these drugs. In this case, with the appearance of adverse reactions, it is necessary to suspend the administration of the solution, assess the patient's condition, and take adequate measures.

If used correctly, undesirable effects are unlikely.

Overdose:

Symptoms: hyperglycemia, glucosuria, hyperglycemic hyperosmolar coma, hyperhydration, disturbance of water-electrolyte balance, acute left ventricular failure. Signs and symptoms of overdose associated with additional drugs when using a solution of dextrose as a solvent for other drugs are determined by the properties of these drugs.

Treatment: When symptoms of an overdose appear, suspend the introduction solution, assess the patient's condition, introduce short-acting insulin, if necessary, maintain symptomatic therapy.

Interaction:

When mixed with other drugs, you need to visually check for compatibility.

Special instructions:

Treatment should be carried out under conditions of regular and careful observation. Clinical and biological parameters, in particular plasma glucose concentration, fluid balance and plasma electrolytes, should be monitored on a regular basis and throughout the treatment period.

In the case of hyperglycemia, the rate of infusion should be carefully adjusted or the administration of short-acting insulin is prescribed. If necessary, potassium can be added.

Patients who are given high doses of dextrose solution should be monitored for development of hypervolemia, cardiac, pulmonary or severe renal failure and / or oliguria / anuria.

It is not recommended to apply the solution after acute ischemic stroke, since hyperglycemia is associated with increased ischemic damage to the brain and prevents recovery.

When carrying out any intravenous infusion, it is necessary to observe the patient's condition. Patients with diabetes mellitus are administered dextrose under the control of blood sugar and urine. In the case of administering infusion of dextrose solution, patients with kidney disease or a diabetic patient should carefully monitor glucose concentration and, if necessary, add short-acting insulin and / or potassium.

The administration of the dextrose solution should not occur simultaneously, before or after the infusion of blood with the same equipment because of the risk of hemolysis and aggregation of red blood cells.

Apply only a clear solution, with no visible mechanical impurities and if the packaging is not damaged. Enter directly after connecting to the infusion system.

Do not use a series connection of plastic containers. This can lead to air embolism due to sucking in the air left in the first container, which can occur before the solution from the next container arrives. The solution should be administered with the use of sterile equipment in compliance with the rules of aseptic and antiseptic.To avoid ingress of air into the infusion system, it should be filled with a solution.

Adding substances can be administered before infusion or during infusion through the injection site (port for drug administration).

When using additives before parenteral administration, it is necessary to check compatibility. Complete and thorough mixing in aseptic conditions is mandatory. Solutions containing additional substances should be used immediately and not stored.

Effect on the ability to drive transp. cf. and fur:

The drug does not affect the ability to drive vehicles and work with mechanisms.

Form release / dosage:

Solution for infusions, 10%.

Packaging:

For 200, 250, 400 or 500 ml in a single-use container with a ring for suspension or without it. Each container is sealed with a polyethylene or polypropylene cap with a foil or first opening ring.

One container, together with the instruction for use, is placed in a cardboard package (bundle).

Without a cardboard package: 30, 24, 15 or 12 containers of 200 ml volume, 250 ml, 400 ml, 500 ml with the appropriate number of instructions for use are placed in boxes of cardboard corrugated with partitionsor gratings.

Storage conditions:

In the dark place at a temperature of 5 to 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LP-002229

Date of registration:16.09.2013

Expiration Date:16.09.2018

The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia

Manufacturer: & nbsp

OZON PHARM, LLC Russia

Representation: & nbspOZON PHARM, LLCOZON PHARM, LLC

Information update date: & nbsp03.05.2017

Illustrated instructions

Instructions

Glucose (Glucose)